Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD
Published: Tuesday, Jan 09, 2018



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.
SELECTED
LANGUAGE


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x